Shots:

• The first patient has been dosed in P-II CIBI112A201 clinical trial evaluating IBI112 (SC- anti-IL-23p19 mAb) in patients with moderate-to-severe PsO
• The primary objective of the study is to evaluate the efficacy of IBI112 at different doses. The safety of drugs & difference of administration interval b/w the different therapeutic regimens will also be investigated
• The results from the P-I trial for IBI112- demonstrated a favorable safety and tolerability profiles & preclinical data demonstrated that IBI112 has a clear target- well-elucidated MoA- and anti-inflammatory effect that provide a more effective treatment option to patients

 Ref: Prnewswire | Image: Innovent